Ascendis Pharma A (ASND) Invested Capital (2012 - 2026)

Ascendis Pharma A has disclosed Invested Capital across 15 years of filings, most recently posting $340.1 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $340.1 million, up 85.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 33.69% YoY), and the FY2025 annual result was $825.3 million, up 2.85% from the prior year.
• Invested Capital came in at $340.1 million for Q1 2026 at Ascendis Pharma A, down from $825.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $825.3 million in Q4 2025 to a low of $94.1 million in Q2 2023.
• The 5-year median for Invested Capital is $214.3 million (2024), against an average of $373.9 million.
• Across the five-year window, Invested Capital slumped 87.58% in 2023 and jumped 85.19% in 2026, its largest moves.
• Ascendis Pharma A's Invested Capital stood at $787.4 million in 2022, then slumped by 31.87% to $536.4 million in 2023, then soared by 49.59% to $802.4 million in 2024, then increased by 2.85% to $825.3 million in 2025, then plunged by 58.79% to $340.1 million in 2026.
• The last three Invested Capital figures came in at $340.1 million (Q1 2026), $825.3 million (Q4 2025), and $273.3 million (Q3 2025), per Business Quant data.